FourThought Financial’s Travere Therapeutics TVTX Stock Holding History

FourThought Financial’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$6K	Hold	252	–	–	﹤0.01%	1156
2022 Q2	$6K	Sell	252 -152	-38%	-$3.82K	﹤0.01%	1141
2022 Q1	$10K	Hold	404	–	–	﹤0.01%	1050
2021 Q4	$13K	Hold	404	–	–	﹤0.01%	1032
2021 Q3	$9K	Hold	404	–	–	﹤0.01%	1126
2021 Q2	$5K	Hold	404	–	–	﹤0.01%	1229
2021 Q1	$10K	Hold	404	–	–	﹤0.01%	1066
2020 Q4	$11K	Buy	+404	New	+$9.43K	﹤0.01%	1009

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

FourThought Financial's TVTX Position: Q3 2022 in Review

FourThought Financial held its Travere Therapeutics (TVTX) position steady in Q3 2022 at 252 shares worth $6K. The position accounts for ﹤0.01% of the portfolio, ranked #1156.

FourThought Financial first reported a position in TVTX in Q4 2020 and has held it in 8 quarters since. The position peaked at $13K in Q4 2021. 171 funds tracked by Wall St. Rank hold TVTX as of Q3 2022.

FourThought Financial held 252 shares of Travere Therapeutics worth $6K as of Q3 2022.
FourThought Financial left its Travere Therapeutics share count unchanged in Q3 2022.
Travere Therapeutics made up ﹤0.01% of FourThought Financial's portfolio in Q3 2022, its #1156 holding.
FourThought Financial first reported a position in Travere Therapeutics in Q4 2020 and has held it in 8 quarters since.
FourThought Financial's Travere Therapeutics position peaked at $13K in Q4 2021.
171 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2022.

Based on FourThought Financial's 13F filing for Q3 2022, filed 21 Nov 2022.